← Back to all signals
RESEARCH PAPER ANALYSIS

Novel TROP2 antibody-drug conjugates for treatment of HER2-negative metastatic breast cancer patients with brain metastases: a promising option☆.

AI interpretation is pending for this paper.

Open original publication →
PMID40359710
JournalESMO open
Publication Date2025-05-12
Ingested2026-08-02 12:04 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

BACKGROUND: ESG401 is a further optimized antibody-drug conjugate comprising a humanized anti-trophoblast cell-surface antigen 2 immunoglobulin G1 monoclonal antibody conjugated to SN-38, a topoisomerase I inhibitor, via a proprietary novel stable linker. The analysis aimed to explore the efficacy of ESG401 in human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) patients with brain metastases (BMs), a population urging significant clinical need with limited systematic treatment options. PATIENTS AND METHODS: This subgroup analysis was conducted as part of an open-label, multi-dose, dose-escalation, and cohort-expansion multicenter phase I trial. Eligible participants were aged 18-75 years and had locally advanced or metastatic solid tumors. For this subgroup analysis, patients with histologically confirmed HER2-negative BC and BMs were enrolled. Efficacy endpoints included overall objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS). Intracranial-specific endpoints included intracranial ORR (iORR), intracranial DCR (iDCR), and intracranial PFS. This trial is registered at ClinicalTrials.gov, NCT04892342. RESULTS: Among 17 patients with efficacy-evaluable BMs, the iORR was 41% (7/17) [95% confidence interval (CI) 18.4% to 67.1%] including 3 patients achieving an intracranial complete response. The iDCR was 76% (13/17) (95% CI 50.1% to 93.2%). The overall ORR was 53% (9/17) (95% CI 27.8% to 77.0%), the overall DCR was 71% (12/17) (95% CI 44.0% to 89.7%), and the medium PFS was 5.7 months. The safety profile was consistent with previous reports. CONCLUSIONS: These findings suggest that ESG401 is a promising and well-tolerated treatment option for BMs.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Pharmacological thromboprophylaxis following ventriculoperitoneal shunt insertion: a single-centre experience of thromboembolic and bleeding outcomes. Acta neurochirurgica 66.5 2 Design principles of prosthetic reconstruction after pelvic tumor resection: a systematic review and perspective from modular systems to 3D-printed personalized solutions. Journal of orthopaedic surgery and research 73.9 3 Ultrasound-guided versus conventional sinus tract laser closure for adolescent sacrococcygeal pilonidal disease: a retrospective comparative study. Techniques in coloproctology 68.4 4 Biallelic MCM10 Deficiency Presenting with Natural Killer Cell Deficiency, Poikiloderma and EBV-Associated Malignancy. Journal of clinical immunology 56.0 5 A qualitative exploration of the psychosocial burden and coping among adolescents and young adults with hematologic malignancies. BMC cancer 64.1 6 Preliminary Psychometric Evaluation of an Ultraviolet Radiation-Related Questionnaire in a Case-Control Sample. Ocular oncology and pathology 70.4 7 Forty Years Later-Complications and Mortality Associated with Cultured Epithelial Autografts in Burn Patients: A Systematic Review. Bioengineering (Basel, Switzerland) 78.1 8 Early Cardiotoxicity in Pediatric Patients with Acute Lymphoblastic Leukemia and Hodgkin Lymphoma: Incidence, Risk Factors, and Clinical Implications. Children (Basel, Switzerland) 74.62 9 Evaluating the Role of Anti-PEG Antibodies in Hypersensitivity to PEG-Asparaginase Through Clinically Relevant Cut-Points Defined by ELISA and Surface Plasmon Resonance. Pharmaceutics 62.0 10 Pediatric Microbiota: Evidence and Future Perspectives-A Conference Report. Microorganisms 65.0 11 A Bias-Aware Analytic Framework for Real-World Data with AI-Audited Workflows: Application to Opioid Ordering in Pediatric Oncology. Bioengineering (Basel, Switzerland) 73.2 12 All-Trans Retinoic Acid Nanocrystals for Enhanced Anticancer Activity Against Neuroblastoma Cancer Stem Cells. Pharmaceutics 53.3 13 Contribution of MTHFR C677T and A1298C Variants to Retinoblastoma Risk in Mexican Children. Genes 64.5 14 EBUS-Guided Cryobiopsy in a Pediatric Inflammatory Mediastinal Tumor With ROS1 Fusion: A Case Report. Pediatric pulmonology 39.0 15 Epidemiology of Kaposi's Sarcoma in Uzbekistan, 2016-2024: Gender-, Age-, and Region-Specific Differences. Asian Pacific journal of cancer prevention : APJCP 37.0 16 Design and Validation of Evidence-Based Peripheral Chemotherapy-Induced Neuropathy Guideline Among the Children with Cancer. Asian Pacific journal of cancer prevention : APJCP 75.34 17 Institutional and Demographic Barriers to Cervical Cancer Screening among Women in Rivers State, Nigeria. Asian Pacific journal of cancer prevention : APJCP 59.5 18 Endoscopic endonasal management of giant pediatric craniopharyngioma. Neurosurgical focus: Video 54.0 19 Keyhole endoscopic resection of pediatric craniopharyngioma via a precoronal transventricular transforaminal approach: "small door, big win.": Two-dimensional operative video. Neurosurgical focus: Video 54.0 20 Subpial dissection technique in endoscopic endonasal surgery for craniopharyngiomas with supradiaphragmatic extension. Neurosurgical focus: Video 35.0 21 Modern craniopharyngioma management: three illustrative cases with distinct therapeutic strategies. Neurosurgical focus: Video 62.04 22 Management of a giant pediatric craniopharyngioma: staged endoscopic endonasal and cranial approaches. Neurosurgical focus: Video 54.0 23 Excision of pediatric craniopharyngioma with complicated features: the value of additional "tailored" cavernous sinus exposure in the standard pterional approach. Neurosurgical focus: Video 56.4 24 Incidental Mandibular Intraosseous Findings in Neurofibromatosis Type 1: CBCT and MRI Features Influencing Clinical Management. Nigerian journal of clinical practice 60.8 25 Mitochondria as Key Players in Sarcoma Development, Progression and Drug Resistance: From Mechanistic Insights to New Treatment Opportunities. Biomolecules 70.6 26 Anodal Transcranial Direct Current Stimulation Reduces Neuroinflammation and Cholinergic Dysregulation After Young Adult Traumatic Brain Injury. Biomolecules 41.7 27 The Antigen-Presentation Bottleneck in Pediatric Solid Tumors: Developmental Antigens, MHC-I Suppression, and Therapeutic Restoration of Tumor Immune Recognition. Biomolecules 66.44 28 Factors Associated with Ventriculoperitoneal Shunt Placement Following Posterior Fossa Tumor Resection in Children: A Systematic Review and Meta-Analysis. Medicina (Kaunas, Lithuania) 75.0 29 Clinical outcomes and prognostic factors in pediatric acute myeloid leukemia with monocytic differentiation: a single-center cohort study from Egypt. Frontiers in oncology 77.8 30 Multi-cohort screening of PANoptosis-related genes reveals PARP1 as a key target, and AZD5305 exerts anti-tumor effects in neuroblastoma. Frontiers in oncology 62.2 31 Extensive vertebral compression fractures as the initial manifestation of childhood B-cell acute lymphoblastic leukemia despite limited peripheral blood abnormalities: a case report. Frontiers in pediatrics 51.4 32 Cervical cancer screening willingness and associated health beliefs among predominantly college-educated young women attending gynecology clinics in Shenzhen, China. Frontiers in public health 59.0
PATIENT-FRIENDLY SUMMARY

Novel TROP2 antibody-drug conjugates for treatment of HER2-negative metastatic breast cancer patients with brain metastases: a promising option☆.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic